1. Market Research
  2. > Cancer
8 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Oncology Drug Report: Zydelig | Idelalisib – 2011 -2016 analysis; 2017-2021 expectations

  • $ 308
  • January 2017
  • 52 pages

LONG-TERM DATA IN CLL kemia, follicular lymphoma and small lymphocytic lymphoma: PRESS RELEASE ## ## Sep 2014 European Commission grants Marketing Authorization for Gilead' s Zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular

  • Lymphoma
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Roche Group

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 75 pages

Rituxan is the first monoclonal antibody approved for lymphomas.

  • Lymphoma
  • Therapy
  • North America
  • United States
  • Seattle Genetics, Inc.

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 71 pages

REVLIMID IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA.

  • Cancer Hormonal Therapy
  • Lymphoma
  • Therapy
  • United States
  • Celgene Corporation

Oncology drug report - Xalkori - crizotinib - 2011-2015 analysis; 2016-2021 expectations

  • $ 308
  • December 2016
  • 48 pages

Anaplastic lymphoma kinase is very small subtype of NSCLC accounting for ~##% of total NSCLC patients.

  • Lung Cancer
  • Lymphoma
  • Therapy
  • United States
  • Pfizer Inc.

Valchlor - mechlorethamine Oncology drug report : 2014-2015 analysis; 2016-2021 expectations

  • $ 308
  • December 2016
  • 40 pages

Joanne and Peter Haas Jr. professor for cutaneous lymphoma research, professor of dermatology, and director, Multidisciplinary Cutaneous Lymphoma Clinic, Stanford University School of Medicine.

  • Lymphoma
  • Therapy
  • United States
  • Actelion Ltd
  • Ceptaris Therapeutics, Inc.

Oncology drug report - Darzalex - Daratumumab - 2015 analysis; 2016-2021 expectations

  • $ 308
  • December 2016
  • 52 pages

Darzalex also granted orphan designation for follicular lymphoma.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States

Blincyto | blinatumomab - Oncology drug report: 2014-2015 analysis; 2016-2021 expectations

  • $ 308
  • December 2016
  • 36 pages

Blincyto|blinatumomab Oncology drug report: 2014-2015 analysis, 2016-2021 expectations December 2016 Blincyto | blinatumomab 2014-2015 analysis; 2016-2021 expectations Expensive drug in a niche market Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Clinical Trial
  • Immunotherapy
  • Therapy
  • United States
  • Amgen Inc.

Oncology (1985-2016) - 157 cancer drugs -Ranking and detailed regulatory approval profiles

  • $ 2052
  • November 2016
  • 523 pages

THE ANTIBODY HAS BEEN SHOWN TO INDUCE APOPTOSIS IN THE DHL-## HUMAN B-CELL LYMPHOMA LINE.

  • Drug Development
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative


View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on